Product Name: Laforin antibody [C2C3], C-term
Applications: ICC/IF, IHC-P, WB
Predicted Target Size: 37 kDa (note)
Positive Controls: 293T , A431 , HeLa , HepG2 , Raji
Form Supplied: Liquid
Concentration: 1 mg/ml (Please refer to the vial label for the specific concentration)
Purification: Purified by antigen-affinity chromatography.
Full Name: epilepsy, progressive myoclonus type 2A, Lafora disease (laforin)
Background: This gene encodes a dual-specificity phosphatase that associates with polyribosomes. The encoded protein may be involved in the regulation of glycogen metabolism. Mutations in this gene have been associated with myoclonic epilepsy of Lafora. Alternative splicing results in multiple transcript variants. [provided by RefSeq]
Synonyms: EPM2 antibody, MELF antibody, EPM2A antibody, lafora PTPase antibody, laforin antibody, “epilepsy, progressive myoclonus type 2, Lafora disease (laforin) antibody”, LAFPTPase antibody, “epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) antibody”
Cellular Localization: Cytoplasm , Isoform 1: Endoplasmic reticulum , Cell membrane , Isoform 2: Endoplasmic reticulum , Nucleus
CAS NO: 338967-87-6
Product: Pyridoclax
Host: Rabbit
Clonality: Polyclonal
Isotype: IgG
Immunogen: Carrier-protein conjugated synthetic peptide encompassing a sequence within the C-terminus region of human Laforin. The exact sequence is proprietary.
Antigen Species: Human
Species Reactivity: Human
Conjugation: Unconjugated
Storage Buffer: 1XPBS, 40% Glycerol (pH7). 0.01% Thimerosal was added as a preservative.
Storage Instruction: Keep as concentrated solution. Aliquot and store at -20ÂșC or below. Avoid multiple freeze-thaw cycles.
Notes: For In vitro laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Specificity:
PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/25010555?dopt=Abstract
